Buslau 1996.

Study characteristics
Methods	Design: randomised, double‐blind, placebo‐controlled, parallel Duration: 12 weeks Interval of assessment: daily by participant
Participants	Number randomised: 50 (25 each in the active and placebo groups) Sex (M/F): 18/32 total (8/17 in the active group and 10/15 in the placebo group) Age of participants: not mentioned Unit of allocation: whole person Country and setting: Germany, not noted Inclusion criteria of the study Severity of condition: mild to moderate Diagnostic criteria: Hanifin Rajka's criteria Exclusion criteria of the study Not specified
Interventions	Treatment group: 2 capsules daily each with 500 mg of BO Placebo group: 2 capsules daily each with 500 mg of palm kernel oil
Outcomes	ADASI score (method of assessment: mapping with the help of coloured markers)
Notes	Concomitant treatment: not permitted Compliance to treatment: not undertaken Previous treatment: unsure
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	The trial did not specify the method of sequence generation
Allocation concealment (selection bias)	High risk	The trial did not specify the method of allocation concealment
Incomplete outcome data (attrition bias) All outcomes	High risk	7/25 participants in the active group withdrew, and 11/25 in the placebo group withdrew. The trial undertook ITT analysis, but dropouts were not balanced between the groups
Selective reporting (reporting bias)	Low risk	The trial reported all prespecified outcomes
Other bias	Unclear risk	No detail of funding or support was listed
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	This was adequate for participants, but it was unclear if they blinded the clinician outcome assessor